ReviewCancer science2012
Prostate cancer genomics, biology, and risk assessment through genome-wide association studies.
Review in Cancer science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis.Molecular biology reports · 2012Pooled it
- In Silico Analysis of Post-COVID-19 Condition (PCC) Associated SNP rs9367106 Predicts the Molecular Basis of Abnormalities in the Lungs and Brain Functions.International journal of molecular sciences · 2025Article
- Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.Molecular biology reports · 2022Article
- Genetically Predicted Circulating Concentrations of Alanine and Alanine Aminotransferase Were Associated with Prostate Cancer Risk.Clinical epidemiology · 2022Article
- MiR-205-5p Functions as a Tumor Suppressor in Gastric Cancer Cells through Downregulating FAM84B.Journal of oncology · 2022Article
- The Sca-1Stem cells (Dayton, Ohio) · 2020Article
- Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls.Journal of the National Cancer Institute · 2020Article
- The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert.Genes · 2020Review
- TWIST2: A new candidate tumor suppressor in prostate cancer.The Prostate · 2019Article
- FAM84B promotes prostate tumorigenesis through a network alteration.Therapeutic advances in medical oncology · 2019Article
- Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer.Cell reports · 2018Article
- A multi-locus genetic association test for a dichotomous trait and its secondary phenotype.Statistical methods in medical research · 2018Article
- Germline BRCA mutation in male carriers-ripe for precision oncology?Prostate cancer and prostatic diseases · 2018Review
- Upregulation of FAM84B during prostate cancer progression.Oncotarget · 2017Article
- Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study.International journal of medical sciences · 2017Article
- Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Medical oncology (Northwood, London, England) · 2015Article
- Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.Current gerontology and geriatrics research · 2014Review
- Skewed X-chromosome inactivation in patients with esophageal carcinoma.Diagnostic pathology · 2013Article
- Regulators of gene expression as biomarkers for prostate cancer.American journal of cancer research · 2012Article
- Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) is the most common malignancy observed in men. It is evident that genetic factors play some important roles in PC etiology. Recently, genome-wide association studies in diverse ethnic groups have identified more than 40 germline variants of various genes or chromosomal loci that are significantly associated with PC susceptibility, including multiple 8q24 loci, prostate-specific genes, metabolic and hormone-related genes, and many regions where no coding gene is annotated. However, there are only a few variants or genes for which biological significance or functions have been elucidated so far. The greatest challenge related to genome-wide association studies loci in prostate genomics is to understand the functional consequences of these PC-associated loci and their involvement in PC biology and carcinogenesis. There have been attempts to determine PC risk estimations by combining multiple PC-associated variants for clinical tests, and these can identify a very minor population with high risk of PC. However, they cannot distinguish risk of aggressive PC from that of non-aggressive PC. Further identification of PC-susceptibility loci in larger genome-wide association studies cohorts and biological insights gained from such functional analyses have the potential to translate into clinical benefits, including the development of reliable biomarkers, risk estimation, and effective strategies for screening and prevention of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.